CIA
FOLD

CSat Investment Advisory’s Amicus Therapeutics FOLD Stock Holding History

CSat Investment Advisory’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,405
Closed -$20K – 686
2020
Q3 		$20K Buy
1,405
+180
+15% +$2.62K ﹤0.01% 859
2020
Q2 		$18K Buy
+1,225
New +$14.9K ﹤0.01% 862

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CSat Investment Advisory's FOLD Position: Q4 2020 in Review

CSat Investment Advisory sold out of Amicus Therapeutics (FOLD) in Q4 2020, closing a stake of 1,405 shares — an estimated $20K sold.

CSat Investment Advisory first reported a position in FOLD in Q2 2020 and held it in 2 quarters. The position peaked at $20K in Q3 2020. 272 funds tracked by Wall St. Rank hold FOLD as of Q4 2020.

  • CSat Investment Advisory reported no remaining Amicus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • CSat Investment Advisory sold 1,405 Amicus Therapeutics shares in Q4 2020, an estimated $20K.
  • CSat Investment Advisory first reported a position in Amicus Therapeutics in Q2 2020 and held it in 2 quarters.
  • CSat Investment Advisory's Amicus Therapeutics position peaked at $20K in Q3 2020.
  • 272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2020.

Based on CSat Investment Advisory's 13F filing for Q4 2020, filed 12 Feb 2021.